- Home
- IEP vs APGE Comparison
IEP vs APGE Comparison
Compare IEP & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEP | APGE |
|---|---|---|
| Founded | 1987 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IEP | APGE |
|---|---|---|
| Price | $7.51 | $134.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | 809.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 24.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,658,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $35.39 |
| 52 Week High | $9.52 | $134.88 |
Technical Indicators
Market Signals| Indicator | IEP | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 77.78 |
| Support Level | $7.17 | $134.03 |
| Resistance Level | $7.76 | N/A |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.03 | -1.08 |
| Stochastic Oscillator | 39.13 | 65.29 |
Price Performance
Historical ComparisonAbout IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.